CHARLOTTE, N.C. -
April 7, 2016 -
PRLog -- Last month BioNap, Inc. published a detailed report introducing investors to Oasmia Pharmaceuticals , a Swedish-based biopharmaceutical company developing next-generation novel formulations of well-established chemotherapeutic agents through its proprietary nanotechnology platform. Shares of Oasmia are up 50% since that article, and we think the upward momentum in the stock will continue based on some recent positive news.
Swedish-based Oasmia develops improved formulations of cytostatic agents (i.e chemotherapies)
using a proprietary nanotechnology platform called XR-17. XR-17 utilizes nanoparticles derived from Vitamin A to solubilize hydrophobic active pharmaceutical ingredients (API). XR-17 is a clinically and commercially validated technology designed to improve solubility, facilitate administration, enhance the pharmacological profile and bioavailability, and allow for dual encapsulation of water-soluble and water-insoluble APIs in one nanoparticle. The lead product candidate is Paclical®, an improved formulation of the chemotherapeutic agent, paclitaxel.
Today we published an update on Oasmia Pharmaceuticals. We continue to be positive on the fundamental story. To read the update, click here >>
http://www.bionapcfa.com/2016/04/oasmia-looks-to-duplicat...
Account Phone Number